Mary's Medicinals Announces Its Intention to Participate in the Newly Announced Medicare and Medicaid CMS Trial Program with Its Award-Winning Cannabinoid-Based Wellness Products

CMS announced a new BEI framework permitting cannabinoid products with up to 3 mg THC per serving; Mary's Medicinals (subsidiary of MM Brands) intends to participate in the CMS Innovation Center cannabinoid therapy trial across ACO REACH and EOM, with patient access via the LEAD model beginning in 2027. The program will evaluate standardized, full‑spectrum hemp-derived CBD products' impact on patient outcomes and their potential to serve as alternatives to opioids and synthetic prescription drugs. CEO Joe Bayern framed participation as a step toward formalizing natural therapeutic pathways and expanding patient access.

Analysis

This CMS-led shift converts a demand pool that has lived largely outside prescription/reimbursement rails into a trackable, contractable revenue stream — think mid-single-digit penetration of chronic-pain cohorts translating into low- to mid-hundreds of millions in annual addressable spend for compliant suppliers within 2–3 years. The key lever is channel migration: products that meet clinical-grade QA and can be delivered through ACO/oncology supply chains will capture pricing power, while lifestyle/commodity CBD brands will face margin compression from formulary negotiation and bulk dispensing.

Second-order winners include GMP contract manufacturers, accredited testing labs, and CROs that run pragmatic trials for ACOs; these service providers can monetize site-of-care scale and recurring testing fees, a classic shift from one-time retail SKU sales to annuity-style B2B revenue. Conversely, supply bottlenecks (qualified hemp-derived APIs, validated microdosing delivery tech) will bid up input costs for anyone trying to scale quickly, creating a meaningful incumbency advantage for larger, vertically integrated operators.

Main risks are evidence and politics: if pragmatic trial readouts fail to show opioid-sparing or cost-effectiveness in elderly/oncology cohorts, coverage could be narrowed rapidly, collapsing pricing and adoption within 6–24 months. Another path to reversal is regulatory tightening (scheduling, state conflicts) or adverse-event signals in frail populations; monitor interim ACO/EOM protocol results and any CMS pricing guidance as 3–18 month binary catalysts.

Key Decisions for Investors

• Initiate a tactical overweight in vertically integrated US MSOs (example: CURLF) — timeframe 6–18 months. Size as 1.0–1.5% NAV position in equities or buy a 9–15 month call spread to cap downside. Rationale: first movers with GMP, speciality-pharmacy hookups, and distribution in ACO-relevant states can capture formulary contracts; target 30–50% upside if they secure regional ACO dispensing agreements, downside capped to ~40% on regulatory headlines.
• Buy exposure to clinical services providers (IQV) over 12 months — 0.5–1.0% NAV. IQVIA-style CROs should win trial/RWE budgets from ACOs and payers; expected modest re-rating (10–20%) on sustained contract flow. Risk: trial budgets can be lumpy; hedge with short-dated hedges if macro risk spikes.
• Pair trade: long a regulated MSO (CURLF) / short pure-play consumer CBD (CWBHF) — 6–12 months. Trade entry when broader cannabis ETFs rally; target pair return 20–40% if reimbursement channel adoption accelerates. Stop the pair if CMS issues restrictive coverage guidance or if stops are hit at 15% adverse move.
• Event hedge: buy protection (puts) on consumer CBD names with concentrated retail exposure and no GMP certifications (examples: CWBHF) expiring 9–12 months out. Rationale: downside asymmetric if formulary wins concentrate demand in certified suppliers; cost is insurance against fast repricing.